USUS

News

Select Year

Menicon acquires Rose K, the world’s largest brand for keratoconus

2008-10-29

The new acquisition expands Menicon's presence in the global GP contact lens market.

Nagoya, Japan, 15 October 2008 Menicon Co., Ltd. and Rose K International Limited announce that the two companies reached an agreement for Menicon to acquire 100% of the ownership of Rose K, effective as of 1 October 2008. With this acquisition, Dr. Paul Rose and Mr. Ian Jennings, founders and owners of Rose K International Limited, who have grown the Rose K business from little New Zealand to a global business that has established the Rose K lens as the market leader for keratoconus, will join the global Menicon group and continue to act as the main figures of the global Rose K operations. Menicon will allocate a substantial amount of resources to further grow the Rose K business world-wide, while maintaining and reinforcing the business relation with the existing labs. With the new acquisition, Menicon continue its global expansion on the GP contact lens segment.

Read More

Menicon undertakes with the Novovision clinic a paediatric myopia control clinical trial

2008-06-23

Nagoya, Japan Although previous studies suggest that orthokeratology contact lens wear slows the axial length growth of the eye in children with progressing myopia, some limitations in the methodology employed have been evident. Using a rigorous study design and precise optical measuring instruments, Menicon Co., Ltd and the Novovision Clinic in Madrid are undertaking the Myopia Control with Orthokeratology contact lenses in Spain (MCOS) study to compare the axial length growth between white European myopic children wearing orthokeratology contact lenses (OK) and distance single-vision spectacles (SP) over a 2 year period. In this prospective, single-centre clinical trial, sixty two subjects 6 to 12 years of age, and with myopia of -0.75 to -4.00 D and astigmatism = 1.00 D were randomly allocated wear OK or SP correction. Measurements of axial length (using partial coherence interferometry, Zeiss IOLMaster), anterior chamber depth, corneal topography, cycloplegic refraction and visual acuity are being performed at 6 month intervals. To date, no subjects have withdrawn from the study, no adverse events were evident and no contact lens fitting modifications were required in the OK group.

Read More

Newsletter for professional